Nuklearmedizin-nuclear Medicine最新文献_第7页

A Case of Chorea-Acanthocytosis with FDG PET/CT Imaging. 舞蹈病-棘细胞增多症1例FDG PET/CT成像。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-06 DOI: 10.1055/a-1780-8463

H. Uslu, Asuman Orhan Varoglu, M. Tatoğlu, Emrah Kılıçaslan

引用次数: 0

[Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios]. [预测Lu-177-PSMA治疗后的出院标准-几种情况的讨论]。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-01 Epub Date: 2022-02-15 DOI: 10.1055/a-1697-8126

Wolfgang Tilman Kranert, Benjamin Bockisch, Jennifer Wichert, Daniel Gröner, Amir Sabet, Justus Baumgarten, Linh Quyen Christina Nguyen Ngoc, Frank Grünwald, Christian Happel

{"title":"[Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios].","authors":"Wolfgang Tilman Kranert, Benjamin Bockisch, Jennifer Wichert, Daniel Gröner, Amir Sabet, Justus Baumgarten, Linh Quyen Christina Nguyen Ngoc, Frank Grünwald, Christian Happel","doi":"10.1055/a-1697-8126","DOIUrl":"https://doi.org/10.1055/a-1697-8126","url":null,"abstract":"Aim: The aim is to add a pragmatic contribution to the discussion of an algorithm to discharge patients treated with Lu-177-PSMA under the aspect of radiation protection. This also may be applied to therapies with other radioactive tracers in the future.Material and methods: 478 cycles of Lu-177-PSMA-617 (140 patients) were analyzed. The remaining activity in the patient and the dose rate were correlated. From frequent intratherapeutic measurements (biexponential fit) scenarios for discharging patients are deduced.Results: Thirty-four per cent of all patients treated with Lu-177-PSMA received 3 to 5 cycles per calendar year. The dose limit of 1 mSv per calendar year (German Law) at a distance of 2 m from the patient would be exceeded in 10 % and 15 % of the treated patients if discharged 72 hours after treatment given 3 and 4 cycles per calendar year, respectively. Mean specific dose rate was 0.00462µSv/(h MBq) at a distance of 1 m. A universal correlation between dose rate and the remaining activity in the patient could not be found.Conclusion: The multi cycle concept of the therapies with Lu-177 PSMA has to be taken into account prospectively when discharging the patients. Given the physical half-life of Lu-177 an anticipation of 4 treatment cycles per calendar year leads to a clearly arranged, conservative rule.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 2","pages":"111-119"},"PeriodicalIF":1.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39789367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radioiodine Uptake of a Benign Peritoneal Cyst on 131-I Whole-body Scan in a Patient Treated for Papillary Thyroid Cancer. 131-I全身扫描对良性腹膜囊肿放射性碘摄取的影响。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-01 Epub Date: 2021-12-16 DOI: 10.1055/a-1699-1595

Mardjan Dabir, Juliane Limberg, Andreas Krieg, Christina Antke, Lino M Sawicki

引用次数: 0

The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml. 18F-PSMA-1007 PET/CT在PSA <10 ng/ml明确治疗后早期复发前列腺癌患者中的诊断价值

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-01 DOI: 10.1055/a-1759-1603

T. Lengana, I. Lawal, C. Janse Van Rensburg, K. Mokoala, E. Moshokoa, Sfiso Mazibuko, C. Van de Wiele, A. Maes, M. Vorster, M. Sathekge

{"title":"The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.","authors":"T. Lengana, I. Lawal, C. Janse Van Rensburg, K. Mokoala, E. Moshokoa, Sfiso Mazibuko, C. Van de Wiele, A. Maes, M. Vorster, M. Sathekge","doi":"10.1055/a-1759-1603","DOIUrl":"https://doi.org/10.1055/a-1759-1603","url":null,"abstract":"AIM\u0000The prostate bed is one of the common sites of early recurrence of prostate cancer. The currently used PSMA ligands (68Ga-PSMA-11 and 99mTc-PSMA) undergo early urinary clearance resulting in interfering physiological activity within and surrounding the prostate. This can result in sites of cancer recurrence being obscured. 18F-PSMA-1007 has an advantage of delayed urinary clearance thus the prostate region is reviewed without any interfering physiological activity. The aim of this study was to determine the diagnostic performance of 18F-PSMA-1007 PET/CT in patients with early biochemical recurrence after definitive therapy.\u0000\u0000\u0000METHODS\u0000Forty-six Prostate cancer (mean age 66.7±7.5, range 48-87 years) presenting with biochemical recurrence (median PSA 1.6ng/ml, range 0.1-10.0) underwent non-contrast-enhanced 18F-PSMA-1007 PET/CT. PET/CT findings were evaluated qualitatively and semiquantitatively (SUVmax) and compared to the results of histology, Gleason grade, and conventional imaging.\u0000\u0000\u0000RESULTS\u0000Twenty-four of the 46 (52.2%) patients demonstrated a site of recurrence on 18F-PSMA-1007 PET/CT. Oligometastatic disease was detected in 15 (32.6%) of these patients. Of these 10 (37.5%) demonstrated intra-prostatic recurrence, lymph node disease was noted in 11 (45.8%) whilst two patients demonstrated skeletal metastases. The detection rates for PSA levels 0-<0.5, 0.5-<1, 1-2, >2 were 31.3%, 33.3%, 55.6% and 72.2% respectively. 7 (29.2%) of the positive patients had been described as negative or equivocal on conventional imaging. An optimal PSA cut-off level of 1.3ng/ml was found.\u0000\u0000\u0000CONCLUSION\u000018F-PSMA-1007 demonstrated good diagnostic performance detecting sites of recurrence. Its ability to detect sites of recurrence in the setting of early biochemical recurrence will have a significant impact on patient management.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"20 1","pages":"120-129"},"PeriodicalIF":1.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89819026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Durchführung und Befundung der 123I-mIBG-Szintigraphie bei Kindern und Jugendlichen mit Neuroblastom (Version 3) – DGN-Handlungsempfehlung (S1-Leitlinie), Stand: 2/2020 – AWMF-Registernummer: 031-040 在神经细胞血脉的儿童和青少年身上执行和公布37i mig sgt stigraphin(第3版本)，听证内容:2/2020 / awmf参数0040

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-01 DOI: 10.1055/a-1778-3052

M. Schmidt, B. Decarolis, C. Franzius, B. Hero, T. Pfluger, J. Rogasch, T. Simon

引用次数: 2

Radioembolization, Principles and indications. 放射栓塞，原理和适应症。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-03-30 DOI: 10.1055/a-1759-4238

H. Ahmadzadehfar, H. Ilhan, M. Lam, M. Sraieb, L. Stegger

引用次数: 4

Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine. 分化型甲状腺癌的个体化治疗:手术结合放射性碘成像和治疗的价值——来自外科和核医学的德国立场文件。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-03-17 DOI: 10.1055/a-1783-8154

M. Schmidt, P. Bartenstein, J. Bucerius, M. Dietlein, A. Drzezga, K. Herrmann, C. Lapa, K. Lorenz, T. Musholt, J. Nagarajah, C. Reiners, C. Sahlmann, M. Kreissl

{"title":"Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine.","authors":"M. Schmidt, P. Bartenstein, J. Bucerius, M. Dietlein, A. Drzezga, K. Herrmann, C. Lapa, K. Lorenz, T. Musholt, J. Nagarajah, C. Reiners, C. Sahlmann, M. Kreissl","doi":"10.1055/a-1783-8154","DOIUrl":"https://doi.org/10.1055/a-1783-8154","url":null,"abstract":"A consensus statement about indications for post-surgical radioiodine therapy (RIT) in differentiated thyroid cancer patients (DTC) was recently published by the European Thyroid Association (ETA) 1. This publication discusses indications for RIT on the basis of an individual risk assessment. Many of the conclusions of this consensus statement are well founded and accepted across the disciplines involved. However, especially from the perspective of nuclear medicine, as the discipline responsible for indicating and executing RIT, some of the recommendations may require further clarification with regard to their compatibility with established best practice and national standards of care. Assessment of the indications for RIT is strongly dependent on the weighing up of benefits and risks. On the basis of longstanding clinical experience in nuclear medicine, RIT represents a highly specific precision medicine procedure of proven efficacy with a favorable side-effect profile. This distinguishes RIT significantly from other adjuvant oncological therapies and has resulted in the establishment of this procedure as a usually well-tolerated, standard safety measure. With regard to its favorable risk/benefit ratio, this procedure should not be unnecessarily restricted, in the interest of offering reassurance to the patients. Both patients' interests and regional/national differences need to be taken into account. We would therefore like to comment on the recent consensus from the perspective of authors and to provide recommendations based on the respective published data.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"27 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79248613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

18F Choline PET/CT in a patient with HRPT2 mutation: Detecting parathyroid carcinoma recurrence and concomitant breast carcinoma. HRPT2突变患者的18F胆碱PET/CT:检测甲状旁腺癌复发和合并乳腺癌。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-02-01 Epub Date: 2021-11-29 DOI: 10.1055/a-1670-9315

Konrad Christof Radzikowski, Gundula Rendl, Mohsen Beheshti, Christian Pirich

引用次数: 3

[The Baker's cyst - a blunt sword of Damokles in radiosynoviorthesis (RSO)?] 贝克囊肿-放射滑膜术(RSO)中的一把钝剑?］

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-02-01 Epub Date: 2021-10-29 DOI: 10.1055/a-1650-9513

Willm Uwe Kampen, Lutz S Freudenberg, Manfred Fischer, Rigobert Klett

{"title":"[The Baker's cyst - a blunt sword of Damokles in radiosynoviorthesis (RSO)?]","authors":"Willm Uwe Kampen, Lutz S Freudenberg, Manfred Fischer, Rigobert Klett","doi":"10.1055/a-1650-9513","DOIUrl":"https://doi.org/10.1055/a-1650-9513","url":null,"abstract":"The existence of a popliteal Baker's cyst was regarded as a contraindication for radiosynoviorthesis of the knee joint since decades. A so-called \"ventile mechanism\" was discussed leading to a significant concentration of the intraarticularly applied, high energy beta emitting radiopharmaceutical yttrium-90-colloid in the cyst. This cyst arises from a bursa beneath the tendon of the medial head of the gastrocnemius muscle, normally communicating with the knee joint space. Since the cyst wall is much thinner than the knee joint capsule, a radiogenic rupture of the cyst was feared, leading to severe radiogenic necroses of the surrounding soft tissue. Due to this potential hazard, knee joint ultrasound is mandatory prior to radiosynoviorthesis to check for any popliteal cysts. New studies however decline the risk of a radiogenic cyst rupture after an appropriately performed radiosynoviorthesis of the knee joint.In case of a preexistent cyst rupture, the risk of a radiogenic tissue damage remains an issue and magnetic resonance imaging (MRI) is the method of choice to exclude this potential hazard. However, MRI sometimes leads to equivocal results. Scintigraphy of the knee joint after intraarticular application of Tc-99m-nanocolloid offers the possibility to check for the integrity of the Baker's cyst in these patients to be sure that radiosynoviorthesis will not lead to a relevant extraarticular leakage with soft tissue necroses. This study describes the procedure of intracavitary distribution scintigraphy by means of representative case reports.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 1","pages":"42-48"},"PeriodicalIF":1.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39678365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer. 转移性前列腺癌的Lu-177-PSMA-617放射配体治疗后的治疗结果和影响总生存的因素

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-02-01 Epub Date: 2021-12-16 DOI: 10.1055/a-1670-9500

Charlotte A Schneider, Philipp Täger, Jochen Hammes, Thomas Fischer, Alexander Drzezga, David Pfister, Axel Heidenreich, Matthias Schmidt

{"title":"Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer.","authors":"Charlotte A Schneider, Philipp Täger, Jochen Hammes, Thomas Fischer, Alexander Drzezga, David Pfister, Axel Heidenreich, Matthias Schmidt","doi":"10.1055/a-1670-9500","DOIUrl":"https://doi.org/10.1055/a-1670-9500","url":null,"abstract":"Objective: To examine the clinical benefit of Lu-177-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer (mCRPC).Patients and methods: Between November 2014 and December 2018, a total of 56 consecutive patients (median age 69.5 years; range 55-84 years) with mCRPC were included in this retrospective analysis. Patients received between 1 and 4 therapy cycles with a mean activity of 6.8 GBq per cycle. Biochemical response was evaluated using Prostate Cancer Working Group Criteria 3 (PCWG 3). Survival was assessed using Kaplan-Meier estimates and Cox proportional hazards regression analysis. This retrospective study was approved by the local ethics committee.Results: A total of 139 treatment cycles with Lu-177-PSMA-617 were performed. A decline of 50% or more of prostate-specific antigen (PSA) level occurred in 54% and a PSA decline of any amount in 65% of patients. The estimated median overall survival (OS) was 16 months, in the chemotherapy subgroup 14 months. A longer OS was associated with a PSA-decline ≥50%, more than 2 cycles of therapy, cumulative activity >15 GBq and an initial alkaline phosphatase ≤ 220 [U/l]. These identified predictors remained significant on uni- and multivariate Cox regression analysis. Moreover, 40% of the patients who were non-responders after the first therapy cycle turned into responders after the second one.Conclusion: PSA-decline ≥50%, a cumulative activity >15 GBq and an initial alkaline phosphatase ≤ 220 [U/l] were identified as key predictors of prolonged OS in patients with mCRPC. In contrast rapid clinical deterioration mostly due to skeletal carcinomatosis resulted in early treatment failure.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 1","pages":"25-32"},"PeriodicalIF":1.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39846664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4